You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. PreImplantation Factor plus hypothermia to treat neonatal brain injury

    SBC: BioIncept, LLC            Topic: NICHD

    ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evide ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation of SBP-101 for the Treatment of Acute Pancreatitis

    SBC: SUN BIOPHARMA, INC.            Topic: 300

    Project Summary Pancreatitis is a significant public health problem accounting for over $ Billion of health care costs annually Approximately one third of patients with acute pancreatitis will go on to have recurrent pancreatitis Of those about will progress to chronic pancreatitis a painful disease with an increased risk of both diabetes and pancreatic cancer More than of people w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings

    SBC: Discidium Biosciences, LLC            Topic: NIAID

    Antiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases

    SBC: Azitra Inc.            Topic: NIAID

    PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing Care of the Aged and Dying in Prisons

    SBC: KLEIN BUENDEL, INC.            Topic: NIA

    The United States has the highest rate of incarceration in the world There are over state and federal prisons housing over million prisoners in the United States The demographics of the prison population are shifting Longer sentences and constrained options for early release compound this trend The older adult segment of prison populations has more than tripled since The health ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Superhydrophobic Implantable Surface and D Printing Technology for Targeted Dental Photodynamic Therapy

    SBC: SINGLETO2 THERAPEUTICS LLC            Topic: 100

    Project Summary Abstract Eradication of bacteria that are located in periodontal pockets is a daunting challenge to dentists and oral care professionals Doxycycline or minocycline with scaling and root planing Sandamp RP have been the mainstays but the field urgently needs further advances in perio bacteria eradication A high precision photochemical implement that could be used simultaneousl ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Identifying activators of interferon regulatory factors for neuroprotection

    SBC: Neuralexo, LLC            Topic: 106

    Abstract Stroke is a leading cause of morbidity and mortality in the United States However less than of patients are eligible for the current approved interventions of tissue plasminogen activator or thrombectomy We seek to develop new therapeutics to reduce the extent of damage and functional impairment resulting from ischemic injury to the brain an area of significant unmet medical need ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government